Chardan Capital Comments on EyePoint Pharmaceuticals, Inc.’s FY2025 Earnings (NASDAQ:EYPT)

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of EyePoint Pharmaceuticals in a research note issued to investors on Tuesday, May 7th. Chardan Capital analyst D. Gataulin forecasts that the company will post earnings per share of ($2.63) for the year. Chardan Capital currently has a “Buy” rating and a $28.00 price target on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($1.73) per share.

Other equities analysts have also recently issued research reports about the company. Capital One Financial restated an “overweight” rating on shares of EyePoint Pharmaceuticals in a report on Friday, February 16th. JPMorgan Chase & Co. started coverage on EyePoint Pharmaceuticals in a research report on Monday, January 22nd. They set an “overweight” rating and a $35.00 price target on the stock. StockNews.com downgraded shares of EyePoint Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday. Mizuho reduced their target price on shares of EyePoint Pharmaceuticals from $39.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, HC Wainwright reduced their price objective on EyePoint Pharmaceuticals from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday, January 16th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.14.

EyePoint Pharmaceuticals Stock Performance

NASDAQ:EYPT traded down $0.04 on Friday, hitting $12.63. 72,216 shares of the stock were exchanged, compared to its average volume of 1,125,028. EyePoint Pharmaceuticals has a 52 week low of $5.67 and a 52 week high of $30.99. The stock has a market capitalization of $657.82 million, a price-to-earnings ratio of -6.92 and a beta of 1.70. The company’s 50-day moving average price is $20.34 and its 200 day moving average price is $19.10.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.27. The company had revenue of $14.03 million for the quarter, compared to analysts’ expectations of $8.71 million. EyePoint Pharmaceuticals had a negative return on equity of 61.48% and a negative net margin of 153.84%. During the same quarter in the prior year, the business earned ($0.61) earnings per share.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Entropy Technologies LP bought a new position in EyePoint Pharmaceuticals in the 1st quarter valued at about $279,000. ProShare Advisors LLC acquired a new position in EyePoint Pharmaceuticals in the 1st quarter valued at $209,000. Legacy Capital Group California Inc. bought a new stake in shares of EyePoint Pharmaceuticals during the 1st quarter valued at $699,000. Swiss National Bank acquired a new stake in shares of EyePoint Pharmaceuticals during the 1st quarter worth $1,792,000. Finally, Essex Investment Management Co. LLC increased its position in shares of EyePoint Pharmaceuticals by 1.5% in the first quarter. Essex Investment Management Co. LLC now owns 149,819 shares of the company’s stock worth $3,097,000 after purchasing an additional 2,278 shares during the period. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at EyePoint Pharmaceuticals

In related news, major shareholder Cormorant Asset Management, Lp purchased 850,000 shares of the stock in a transaction on Monday, May 6th. The shares were purchased at an average price of $11.86 per share, with a total value of $10,081,000.00. Following the transaction, the insider now directly owns 8,325,000 shares of the company’s stock, valued at $98,734,500. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 13.05% of the company’s stock.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.